Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) yesterday and set a ...

Financial analyst predicts Bausch & Lomb (BLCO) could be worth $28/share in a potential takeover, with private equity ...

Federal Reserve's rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap ...

This suit was surfaced by Law.com Radar, ALM's source for immediate alerting on just filed cases in state and federal courts.

In a report released yesterday, Larry Biegelsen from Wells Fargo assigned a Buy rating on Bausch + Lomb Corporation (BLCO – Research ...

Bausch + Lomb BLCO. The industry declined 0.6% during this timeframe. The sale, intended to separate both companies, is stuck for quite some time now. Hence, reports of BHC moving forward have ...

Bausch & Lomb (NYSE:BLCO) rose 1.8% in premarket trading after a report about private equity interest in a takeover of the ...

Hedge fund managers sit on the boards of Bausch Health and Bausch + Lomb. They don’t think like your typical corporate board, ...

(Bloomberg) -- Bausch Health Cos. is working with Jefferies Financial Group to explore refinancing some of its debt to aid a long-planned spinoff of its stake in the eye-care company Bausch + Lomb ...

Bausch Health (BHC) shares rallied 11.7% in the last trading session to close at $8.02. This move can be attributable to notable volume with a higher number of shares being traded than in a typical ...